Literature DB >> 11689482

Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina.

G M Sarra1, C Stephens, M de Alwis, J W Bainbridge, A J Smith, A J Thrasher, R R Ali.   

Abstract

The retinal degeneration slow (rds or Prph2(Rd2/Rd2)) mouse, a model of recessive retinitis pigmentosa, lacks a functional gene encoding peripherin 2. This membrane glycoprotein is required for the formation of photoreceptor outer segment discs. The striking feature of the rds mouse is the complete failure to develop outer segments. We have previously examined the short-term effect of gene replacement therapy using an adeno-associated (AAV) vector and demonstrated induction of outer segments and improvement of photoreceptor function. Here we have extended our analysis and have demonstrated that the potential for ultrastructural improvement is dependent upon the age at which animals are treated, but the effect of a single injection on photoreceptor ultrastructure may be long-term. However, there was no significant effect on photoreceptor cell loss, irrespective of the date of administration, despite the improvements in morphology and function. Our investigation excluded procedure-related damage, vector toxicity and immune responses as major factors which might counteract the benefits of photoreceptor restoration, but suggested that transgene over-expression is of significance. These findings suggest that successful gene therapy in patients with photoreceptor defects may ultimately depend upon intervention in early stages of disease and upon accurate control of transgene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689482     DOI: 10.1093/hmg/10.21.2353

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  44 in total

Review 1.  Prevention and therapy in hereditary retinal degenerations.

Authors:  Dorothea Besch; Eberhart Zrenner
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

Review 2.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

Review 3.  Gene therapy for ocular diseases.

Authors:  Melissa M Liu; Jingsheng Tuo; Chi-Chao Chan
Journal:  Br J Ophthalmol       Date:  2010-08-23       Impact factor: 4.638

Review 4.  Gene therapy in the Retinal Degeneration Slow model of retinitis pigmentosa.

Authors:  Xue Cai; Shannon M Conley; Muna I Naash
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 5.  Retinal pigment epithelium differentiation of stem cells: current status and challenges.

Authors:  Basak E Uygun; Nripen Sharma; Martin Yarmush
Journal:  Crit Rev Biomed Eng       Date:  2009

Review 6.  [Viral and nonviral gene therapy for treatment of retinal diseases].

Authors:  J Neidhardt; K Wycisk; B Klöckener-Gruissem
Journal:  Ophthalmologe       Date:  2005-08       Impact factor: 1.059

Review 7.  Nanoparticle applications in ocular gene therapy.

Authors:  Xue Cai; Shannon Conley; Muna Naash
Journal:  Vision Res       Date:  2007-09-06       Impact factor: 1.886

8.  Genetic supplementation of RDS alleviates a loss-of-function phenotype in C214S model of retinitis pigmentosa.

Authors:  May Nour; Steven J Fliesler; Muna I Naash
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 9.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

10.  Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa.

Authors:  Xue Cai; Shannon M Conley; Zack Nash; Steven J Fliesler; Mark J Cooper; Muna I Naash
Journal:  FASEB J       Date:  2009-12-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.